W

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Business Management
Share
Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

Oracle’s stock gets a boost as the OpenAI ecosystem comes back into favor

“It looks like OpenAI is turning things around,” and that’s seen as good news for Oracle, which has a lot riding on the ChatGPT creator’s success.…

Circle agrees to buy cross-border payments firm Tazapay for $400 million

The deal could grant Circle vital, regulated "lastmile" infrastructure, bridging the gap between stablecoins and traditional local banking systems.…

Strive’s SATA nears $1 billion market cap as Strategy’s STRC continues to underperform

SATA’s 13% annualised dividend and resilience around par are helping Strive raise capital and outperform Strategy. Source：CoinDesk

Visa combines VisaNet data with onchain lending to power stablecoin card working capital

Visa's stablecoin settlement volume surpassed a $20 billion annualized run rate, up 15x year over year. Now it wants blockchain lenders to use that data to…

Source：https://www.marketwatch.com/story/novartiss-failed-trial-for-cholesterol-drug-leads-to-broad-biopharma-selloff-2d487746